Autologous bone marrow or blood stem cell transplantation in chronic myeloid leukemia. France Auto Greffe Group.
Forty-seven patients with Ph1-positive chronic myeloid leukemia in transformation (CML) underwent autologous transplantation of peripheral blood stem cells (ABSCT) collected at the original diagnosis before any treatment. They were treated according to 3 consecutive strategies: single transplant (Group I = 17 patients), double transplant (Group II = 13 patients), double transplant followed by recombinant alpha interferon (IFN) (Group III = 17 patients). The actuarial median duration of second chronic phase was 3 months, 10 months and 18 months for Group I, Group II and Group III patients (p less than 0.0001). The encouraging results observed for Group III patients prompted us to propose ABSCT for patients in chronic phase with initial prognostic factors (high-risk CML) suggesting that IFN will not be effective if administered as front-line therapy. To date, 13 patients with high-risk CML underwent ABSCT followed by IFN therapy. Ten patients achieved a complete hematological response following transplantation. Two of 6 evaluable patients had a cytogenetical response 6 months after ABSCT. A longer follow-up is needed to see if the duration of chronic phase may be prolonged.
Reiffers
J
J
Unité de Greffe, CHR Bordeaux, Hôpital Haut-Levêque, Pessac, France.
D000328:Adult; D001752:Blast Crisis / Q000601:surgery*; D016026:Bone Marrow Transplantation; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D014182:Transplantation, Autologous